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The visinin-like 1 (VSNL1) gene encodes visinin-like protein 1, a peripheral biomarker for
Alzheimer disease (AD). Little is known, however, about normal VSNL1 expression in brain
and the biologic networks in which it participates. Frontal cortex gray matter obtained from
209 subjects without neurodegenerative or psychiatric illness, ranging in age from 16 to 91,
was processed on Affymetrix GeneChip 1.1 ST and Human SNP Array 6.0. VSNL1 expres-
sion was unaffected by age and sex, and not significantly associated with SNPs in cis or
trans. VSNL1 was significantly co-expressed with genes in pathways for calcium signal-
ing, AD, long-term potentiation, long-term depression, and trafficking of AMPA receptors.
The association with AD was driven, in part, by correlation with amyloid precursor protein
(APP) expression. These findings provide an unbiased link between VSNL1 and molecular
mechanisms of AD, including pathways implicated in synaptic pathology in AD. Whether
APP may drive increased VSNL1 expression, VSNL1 drives increased APP expression, or
both are downstream of common pathogenic regulators will need to be evaluated in model
systems.
Keywords: visinin-like 1, visinin-like protein 1, Alzheimer disease, co-expression networks, calcium signaling,
synaptic plasticity
INTRODUCTION
Alzheimer disease (AD) is the most prevalent form of dementia in
the United States. It is characterized clinically by declining mem-
ory, progressive loss of cognitive ability, and behavioral changes.
The incidence of AD increases rapidly with increasing age (1). This
suggests a role of brain aging in risk for AD, although the basis of
this age-dependence is not established. Neuropathologically, the
hallmarks of AD are deposition of extracellular amyloid plaques
that are predominantly composed of amyloid-β (Aβ) peptide and
intracellular neurofibrillary tangles (NFTs) comprised of hyper-
phosphorylated microtubule-associated protein tau (2, 3). Other
pathologic changes include synapse and neuron loss, and reactive
gliosis (4).
Among these pathologies, the strongest correlate of cognitive
impairment in individuals with AD is loss of synapses across neo-
cortical regions (5, 6), with excitatory synapses onto dendritic
spines particularly affected (7, 8). Substantial evidence now indi-
cates that aggregation of Aβ into soluble oligomers is a primary
source of synaptotoxicity in AD (9–14). Although studies con-
tinue to elucidate how Aβ acts to eliminate dendritic spines, there
is evidence that soluble Aβ inhibits mechanisms of long-term
potentiation and/or engages mechanisms of long-term depres-
sion, including reducing NMDA receptor dependent Ca2+ influx,
mGlutamate receptor (mGluR) activation, and low level caspase-3
activation (10, 12). The final common mechanism for these path-
ways converge on altered endocytotic recycling of GluR, resulting
in reduced synaptic expression of GluR1 and GluR2 containing
AMPA receptors and synaptic NMDA receptor (15).
Recently, several studies have identified visinin-like protein 1
(Vilip1), a protein encoded by the visinin-like 1 (VSNL1) gene, as
a biomarker of AD. Vilip1 concentrations in cerebrospinal fluid
and plasma are elevated in AD subjects relative to normal controls
(16, 17) and to non-AD dementia subjects (17). Higher levels of
cerebrospinal fluid Vilip1 also predicted a faster rate of cognitive
decline (18). Other biomarkers for AD, such as cerebrospinal fluid
measures of Aβ, tau, and phospho-tau (19), are strongly implicated
in the pathogenesis of AD by genetic, post-mortem, animal model,
and in vitro studies. To date, the evidence for Vilip1 is much more
limited. We reported that genetic variations in VSNL1 were associ-
ated with risk for psychosis in AD (20), a phenotype characterized
by more rapid cognitive deterioration than seen in AD subjects
without psychosis (21, 22). Qualitative studies have reported that
Vilip1 can be detected in association with neuritic plaques and
NFTs in neocortex of AD subjects (23), and may contribute to
phosphorylation of tau and Ca2+-mediated cell death (24).
Vilip1 is a highly brain expressed member of the visinin-like
protein subfamily of neuronal calcium sensors (25). Vilip1, like
other subfamily members appears to modify receptor recycling
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(26). For example, the closely related subfamily member, hip-
pocalcin, is necessary for NMDA receptor dependent long-term
depression via GluR endocytosis (27, 28). Whether Vilip1 has
effects on synaptic plasticity processes implicated in synapse loss in
AD, such as GluR recycling, long-term potentiation, and long-term
depression, is not known. However, Vilip1 has a higher affinity for
Ca2+ than calmodulin, suggesting it may respond to the lower
Ca2+ levels, which induce long-term depression (25).
The above findings are consistent with the hypothesis that
VSNL1/Vilip1 may contribute to the risk for AD, possibly via age-
dependent alterations in expression or by affecting processes that
contribute to synapse or neuronal loss. To date, however, very lit-
tle is known about normal VSNL1 expression in brain, whether it
is modulated by genetic variation, and the brain-related biologic
co-expression networks in which VSNL1 participates. To begin
to address these questions, we assessed VSNL1 expression in two
regions of frontal cortex obtained from 209 subjects spanning the
adult age range, and without evidence of psychiatric or neurode-
generative illness. We found that VSNL1 expression was present
throughout the adult life span and was unaffected by age, sex, and
common genetic variants in cis and trans. VSNL1 co-expression
networks included KEGG pathways for calcium signaling, AD, and
pathways implicated in synaptic pathology in AD.
MATERIALS AND METHODS
SUBJECTS
All of the brain specimens were collected during autopsies con-
ducted at the Allegheny County Office of the Medical Examiner
with permission obtained from the subjects’ next-of-kin. The pro-
tocol used to obtain consent was approved by the University of
Pittsburgh Institutional Review Board (IRB) and Committee for
Oversight of Research Involving the Dead. An independent com-
mittee of experienced clinicians made consensus DSM-IV diag-
noses for each subject, using information obtained from clinical
records and structured interviews with surviving relatives. These
procedures were IRB approved. Samples from a total of 212 sub-
jects without any DSM-IV diagnosis (i.e., including no diagnosis
of a cognitive disorder) were obtained for use in this study.
TISSUE PROCESSING
Upon brain collection, ~2 cm coronal blocks from the right hemi-
sphere were cut through the rostro-caudal extent of the brain
and stored at −80°C. The RNA integrity (RIN) of each brain was
assessed by chromatography (Agilent Bioanalyzer, Santa Clara, CA,
USA). Samples were obtained from two prefrontal cortex (PFC)
regions: Brodmann areas (BA) 11 and 47. These areas were selected
based on prior findings showing robust age-related changes in gene
expression that were highly correlated with other PFC regions
(e.g., BA9) (29). Gray matter samples containing all six layers
and excluding white matter were harvested from three to four
consecutive 20µm sections and stored in Trizol reagent.
RNA ARRAYS
Total RNA was extracted from frozen BA11 and BA47 samples
stored in TRIZOL and were processed for microarray analysis
using GeneChip Human Gene 1.1 ST from Affymetrix according
to manufacturer’s protocol (http://www.affymetrix.com). Gene
expression data were extracted using Expression Console build
Table 1 | Demographic and technical characteristics of human subjects.
Variable N (%) or mean (SD)
Age (years) 50.5 (14.6)
Range 16–91
Sex
Male 166 (79)
Female 43 (21)
Race
Caucasian 178 (85)
African-American 31 (15)
PMI 17.2 (5.9)
Range 4.8–37.5
pH 6.7 (0.3)
Range 5.8–7.6
RIN 8.0 (0.73)
Range 5.9–9.6
PMI, post-mortem interval; RIN, RNA integrity number.
1.2.1.20. The normalization method is based on quantile normal-
ization to eliminate batch effects. Data from arrays were processed
by RMA method. Gene expression probes were processed at gene-
level and taken in log2 scale for further analysis. After normal-
ization, 33,297 gene-level probes remained. Three samples were
removed from study, one due to poor array quality, one due to
outlier effect, and one due to XXY genotype, resulting in a final
sample size of 209 subjects (Table 1).
GENOTYPING
DNA samples for 204 of the subjects were available, and processed
on Affymetrix SNP 6.0 arrays, assessing genotype at 906,600 SNPs.
Genotype calls were generated using Affymetrix Genotyping Con-
sole version 4.1.3. For intensity quality control (QC), we used
Contrast QC, which is the per sample QC test in the Affymetrix
SNP 6.0 intensity array; two samples were removed after QC, leav-
ing a final sample of 202 subjects for genotype measures. Birdseed
v2 algorithm was used for genotyping, using the EM algorithm
to drive a maximum likelihood fit of a two dimensional Gaussian
mixture model.
STATISTICAL ANALYSIS
Age-dependent expression
Linear regression models were fitted to assess the association
between VSNL1 expression level and demographic factors (age,
sex, race). These models included as covariates the technical fac-
tors brain pH and RIN, as both were significantly associated with
VSNL1 expression: p= 7.21e-09 (BA11) and 1.94e-04 (BA47) for
pH association and p= 3.66e-12 (BA11) and 1.16e-08 (BA47) for
RIN association. There was no significant association of VSNL1
expression with post-mortem interval (PMI, p= 0.26 and 0.36 in
BA11 and BA47, respectively) and thus PMI was not included in
the models.
eQTL mapping
eQTL analysis was performed in the 169 Caucasian subjects for
whom genotype data were available. PCA analysis did not indicate
population substructure within this cohort. All subjects had call
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rates >98%. SNPs were filtered out using the following criteria:
(i) sample missing rate >10%, (ii) Minor allele frequency (MAF)
<5%, and (iii) p value of Hardy–Weinberg equilibrium (HWE)
test <10−3. SNPs were defined as in cis if they were located within
50 kbp of VSNL1. All other SNPs were defined as in trans.
The eQTL model adjusted for age, pH, and RIN values (each
was significantly associated with gene expression in both BA11
and BA47) since the effects of those covariates may confound
eQTL findings. The eQTL model with three covariates for a given
genotype was:
Gij = αi + γiXj +
∑3
k=1 βikSjk + ∈ij
in which: Gij: gene expression of gene i of subject j ; αi : intercept
term of gene i; γi: effect of the selected genotype to gene i based on
additive model; Xj: genotype of subject i, 0 (homozygous major
alleles), 1 (heterozygous calls), and 2 (homozygous minor alleles);
βik: the effect of covariates k; k = 1 (age), 2 (pH), and 3 (RIN) in
gene i; Sjk: the value of covariate k of subject j ; k = 1 (age), 2 (pH),
and 3 (RIN);
∈ij∼N (0, 1)
We used the “Matrix eQTL” R package, a recent computation-
ally efficient package for eQTL analysis (30), to detect the desired
trans-eQTLs. We applied the adaptive weighted (AW) Fisher’s
method (31) for meta-analysis to combine eQTL p-values from
two brain regions (BA11 and BA47). The AW Fisher’s method
has the advantage to distinguish study homogeneity and hetero-
geneity by assigning 0 or 1 study (brain region) weights for each
eQTL. Detected eQTLs from the meta-analysis can have three pos-
sible resulting weights: (1,1) meaning detected eQTL in both brain
regions; (1,0) showing detected eQTL in BA11 but not in BA47
and vice versa for (0,1) weight. In order to avoid heterogeneity of
eQTL findings across brain regions, we selected only eQTLs that
were identified in both brain regions with (1,1) weights in the AW
Fisher’s method.
Co-expression pathway analyses
To reveal the co-expression structure of VSNL1, we selected the
top 400 positively and negatively correlated genes in both brain
regions. The minimum observed correlation among the selected
genes was 0.64, and the associated p-values suggest the corre-
sponding false discovery rate (FDR) is <1e-04. Pathway analysis
was performed via over representation analysis based on Fisher’s
exact test using pathway information retrieved from KEGG, BIO-
CARTA, and REACTOME databases. The Benjamini Hochberg
procedure was used to control FDR for pathways (32).
RESULTS
VSNL1 EXPRESSION
There were no significant associations of VSNL1 expression in
either BA11 or BA47 with age, race, or gender (Figure 1).
VSNL1 eQTL ANALYSIS
There was no significant association of VSNL1 expression with
40 genotyped SNPs located in the cis-regulatory region (Table
S1 in Supplementary Material). Examination of the association
of VSNL1 expression with SNPs in trans revealed 27 SNPs with
suggestive evidence of association (p< 10−6, Figure 2; Table
S2 in Supplementary Material). However, no SNPs reached the
threshold for genome wide significance (p< 10−8).
VSNL1 CO-EXPRESSION NETWORKS
We next evaluated VSNL1 co-expression. Although VSNL1 expres-
sion was itself not age dependent, many of its potential co-
expression partners show age-dependent alterations in expression,
including genes related to neurodegeneration (29, 33). Therefore,
we separately evaluated co-expression in subjects under and over
50 years of age. The 400 genes with the greatest positive and neg-
ative correlations with VSNL1 expression in each age group are
shown in Table S3 in Supplementary Material.
The KEGG, BIOCARTA, and REACTOME pathways showing
the most significant loading for genes positively and negatively
correlated with VSNL1 expression are shown in Tables 2 and
3, respectively (all pathways are shown in Table S4 in Supple-
mentary Material). In subjects under 50, VSNL1 was positively
correlated with genes in the KEGG pathway for AD and the BIO-
CARTA pathway for P35 signaling in AD (P35Alzheimers). The
association with the KEGG pathway was driven by correlations
with amyloid precursor protein (APP), ATP2A2, CALM1, CDK5,
CHP, GSK3B, ITPR1, NDUFAB1, NDUFV2, PPP3CA, PPP3CB,
and UQCRH. The association with the P35Alzheimers pathway
was driven by three of the same genes (APP, CDK5, and GSK3B) as
well as PPP2CA. In subjects over 50, the co-expression of VSNL1
with these AD pathways was weakened, with CDK5, CHP, and
NDUFAB1 no longer among the top co-expressed genes.
Other neuronal calcium sensor family members have been
shown to mediate processes dependent on glutamate receptor traf-
ficking, such as long-term potentiation and long-term depression
(27, 28, 34). Although the protein product of VSNL1, Vilip1, is
known to alter availability of α4,β2-nicotinic acetylcholine recep-
tors at the cell membrane via affects on endocytic trafficking (35),
a similar effect on glutamate receptors has not been shown. It is
of some interest, therefore, that among the top pathways iden-
tified by genes positively correlated with VSNL1 expression are
the KEGG pathway for long-term potentiation and REACTOME
pathways for trafficking of AMPA receptors. These associations
include positive correlations with several AMPA receptor sub-
units: GRIA1, GRIA2, and GRIA3. Although not among the top
pathways identified, there was also a significant positive corre-
lation of VSNL1 expression with the KEGG pathway for long-
term depression in both age groups (Table S4 in Supplementary
Material).
DISCUSSION
We evaluated the hypothesis that VSNL1 may contribute to the
development of AD by assessing whether VSNL1 demonstrated
age-dependent expression and by determining the brain-related
biologic co-expression networks in which VSNL1 participates.
VSNL1 expression was present throughout the adult life span,
but was not correlated with subject age. VSNL1 co-expression
networks included AD pathways and pathways implicated in
synaptic pathology in AD, including long-term potentiation, long-
term depression, and trafficking of AMPA receptors. These latter
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FIGURE 1 | VSNL1 expression as a function of age, race, and sex. The correlation of VSNL1 expression levels with age are shown in the first panels for each
area. The second and third panels show the density of expression levels as a function of race and sex. No associations were significant. BA, Brodmann area.
findings provide an unbiased link in support of the hypothesis that
VSNL1/Vilip1 may participate in molecular mechanisms of AD.
We found that VSNL1 is expressed throughout the adult lifes-
pan in human frontal cortex and is independent of subject age.
We, and others, have previously reported that there is a substan-
tial overlap between genes demonstrating age-related changes in
expression and genes involved in the pathogenesis of neurodegen-
erative illnesses, including AD (36). The lack of changes in VSNL1
expression with age in our subjects suggests that any contribution
of VSNL1 to the development of AD is not via this age-dependent
mechanism. However, this does not preclude that VSNL1 expres-
sion could vary with age in other brain regions relevant to AD
pathogenesis, such as the hippocampus. Also, it remains possible
that post-transcriptional processing of VSNL1 into Vilip1 protein
may vary with age. Evaluating that alternative will require future
study of brain Vilip1 levels in an aging cohort.
We had previously identified an association between genetic
variation in VSNL1 and the psychotic phenotype of AD (20).
Because one important mechanism by which genetic variants may
affect risk for neurodegenerative disease is to alter the transcrip-
tion of their gene products in brain (37), we evaluated whether
VSNL1 expression in frontal cortex is associated within or nearby
the VSNL1 locus. We did not detect an association of VSNL1
expression with any of the tested SNPs. However, the possibility
that nearby SNPs, other than the ones tested, affect VSNL1 expres-
sion cannot be excluded. To assess this likelihood, we used data
from the 1000 Genomes project to estimate what proportion of all
common variants (minor allele frequency ≥5%) in VSNL1 were
correlated with the SNPs tested in our analysis. Only 70% of the
common variants were tagged by one or more of our SNPs with
an r2≥ 0.8. The 30% of poorly tagged common variants includes
the most strongly-associated SNP in our GWAS, rs4038131. It is
also possible that genetic variants, including those evaluated in the
current study, may alter VSNL1 expression only in the presence of
neurodegenerative pathology. However, it should be noted that
recent tests of SNPs in the AD risk genes ABCA7, BIN1, CD2AP,
CD33, CLU, CR1, EPHA1, MS4A6A, MS4A6E, and PICALM for
associations with the expression of their respective genes in brain
tissue from AD and healthy control subjects have been largely
negative (38, 39).
Although the focus of our study was on risk for AD, genetic
variants in VSNL1, altered brain VSNL1 mRNA expression, and
altered brain levels of Vilip1 protein have been reported in schiz-
ophrenia (40–42). Of particular relevance to the current report
was the finding that microRNA miR-181b, which is elevated in
schizophrenia, can downregulate VSNL1 expression in model
Frontiers in Psychiatry | Molecular Psychiatry March 2015 | Volume 6 | Article 30 | 4
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FIGURE 2 | Manhattan plot of SNP associations with VSNL1 expression. Associations are shown for each region, and for the weighted average of the two
regions in the meta-analysis. BA, Brodmann area.
systems and correlates with reduced VSNL1 expression in the
superior temporal gyrus in subjects with schizophrenia (40). We
were able to replicate the negative correlation between VSNL1
expression and expression of pre-miR-181b genes in our normal
aging cohort in both BA11 and BA47 (Figure S1 in Supplemen-
tary Material). However, how this normative regulation of VSNL1
by miR-181b might be changed in the presence of AD pathology
and/or genetic variation in VSNL1, and in particular whether they
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Table 2 |Top pathways identified by genes showing positive correlations with VSNL1 expression.
Pathway Age under 50 Age over 50
BA 47 BA 11 AVG BA 47 BA 11 AVG
KEGG
Aldosterone regulated sodium reabsorption 5.63E−03 5.00E−03 1.47E−05 9.00E−03 7.44E−03 1.96E−05
Alzheimers disease 1.20E−04 1.43E−03 1.47E−05 5.29E−03 6.55E−02 3.52E−04
Calcium signaling pathway 4.83E−04 1.08E−04 1.47E−05 1.10E−04 5.21E−03 1.96E−05
Cardiac muscle contraction 9.35E−04 6.19E−04 1.47E−05 8.94E−04 1.34E−03 1.96E−05
Epithelial cell signaling in Helicobacter pylori infection 1.96E−03 1.78E−05 1.47E−05 3.69E−04 2.02E−04 1.96E−05
Long-term potentiation 1.35E−03 1.04E−03 1.47E−05 2.92E−04 6.36E−03 1.96E−05
Oocyte meiosis 2.23E−04 9.68E−06 1.47E−05 2.76E−03 1.17E−03 1.96E−05
Oxidative phosphorylation 2.59E−04 1.59E−04 1.47E−05 7.01E−03 7.93E−03 1.96E−05
Proximal tubule bicarbonate reclamation 4.52E−03 3.60E−03 1.47E−05 5.72E−03 6.82E−03 1.96E−05
Vibrio cholerae infection 1.20E−04 2.10E−06 1.47E−05 8.76E−05 3.23E−06 1.96E−05
WNT signaling pathway 2.61E−03 1.70E−04 1.47E−05 2.88E−04 9.06E−03 1.96E−05
BIOCARTA
AKAP centrosome pathway 1.19E−02 1.30E−02 2.58E−04 1.87E−03 1.67E−02 1.96E−05
CDC42RAC pathway 3.70E−03 2.56E−02 7.89E−05 4.59E−01 1.48E−01 1.13E−01
CHREBP2 pathway 1.17E−03 4.42E−03 1.47E−05 1.10E−03 1.64E−03 1.96E−05
CK1 pathway 5.35E−04 3.60E−03 1.47E−05 4.84E−04 3.06E−02 1.96E−05
CREB pathway 4.45E−03 4.35E−03 1.47E−05 5.62E−03 6.82E−03 1.96E−05
FCER1 pathway 7.74E−03 8.12E−03 2.74E−05 1.01E−02 1.27E−02 1.03E−04
GPCR pathway 1.20E−04 1.67E−03 1.47E−05 3.44E−04 1.27E−02 1.96E−05
HDAC pathway 3.18E−03 3.16E−03 1.47E−05 5.00E−04 4.19E−03 1.96E−05
MEF2D pathway 5.35E−04 2.56E−02 1.47E−05 3.20E−02 3.06E−02 8.39E−04
NDKDYNAMIN pathway 4.52E−03 5.83E−04 1.47E−05 3.73E−02 1.17E−03 1.96E−05
NFAT pathway 5.02E−04 1.74E−03 1.47E−05 1.88E−05 2.67E−03 1.96E−05
NOS1 pathway 3.92E−05 1.04E−03 1.47E−05 1.39E−04 1.80E−03 1.96E−05
P35Alzheimers pathway 5.30E−03 5.45E−03 1.47E−05 5.71E−02 5.43E−02 3.92E−03
PGC1A pathway 1.94E−03 1.74E−03 1.47E−05 4.36E−05 2.67E−03 1.96E−05
VIP pathway 4.04E−04 1.44E−02 1.47E−05 3.15E−03 1.78E−02 1.96E−05
REACTOME
Acetylcholine neurotransmitter release cycle 2.67E−03 1.54E−04 1.47E−05 1.93E−04 4.13E−04 1.96E−05
DARPP32 events 3.92E−05 7.66E−05 1.47E−05 1.02E−04 1.17E−03 1.96E−05
Dopamine neurotransmitter release cycle 7.12E−03 3.91E−06 1.47E−05 8.76E−05 4.97E−06 1.96E−05
Formation of tubulin folding intermediates by CCT TRIC 1.94E−03 8.67E−03 1.47E−05 1.07E−02 1.19E−02 1.03E−04
Glucose regulation of insulin secretion 1.13E−03 6.15E−03 1.47E−05 9.88E−02 3.19E−01 4.45E−02
Glutamate neurotransmitter release cycle 2.31E−03 1.84E−04 1.47E−05 2.68E−04 4.37E−04 1.96E−05
Integration of energy metabolism 1.33E−04 3.60E−03 1.47E−05 2.34E−02 1.57E−01 4.65E−03
Neurotransmitter receptor binding and downstream
transmission in the postsynaptic cell
1.94E−03 2.33E−05 1.47E−05 5.00E−04 2.67E−03 1.96E−05
Neurotransmitter release cycle 5.40E−03 9.68E−06 1.47E−05 1.02E−04 1.15E−05 1.96E−05
Norepinephrine neurotransmitter release cycle 3.89E−03 2.60E−04 1.47E−05 3.44E−04 5.25E−04 1.96E−05
Opioid signaling 1.13E−04 1.44E−04 1.47E−05 3.37E−06 1.30E−03 1.96E−05
PLC beta-mediated events 2.11E−03 4.30E−02 6.76E−05 3.44E−04 5.43E−02 1.96E−05
(Continued)
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Table 2 | Continued
Pathway Age under 50 Age over 50
BA 47 BA 11 AVG BA 47 BA 11 AVG
PLC gamma1 signaling 4.39E−04 9.35E−03 1.47E−05 3.44E−04 1.27E−02 1.96E−05
Regulation of insulin secretion 2.74E−04 3.32E−03 1.47E−05 4.72E−03 9.62E−02 4.34E−04
Regulation of insulin secretion by acetylcholine 5.40E−03 5.66E−03 1.47E−05 1.02E−04 1.00E−02 1.96E−05
Regulation of insulin secretion by free fatty acids 3.70E−03 2.88E−03 1.47E−05 7.73E−05 6.82E−03 1.96E−05
Regulation of insulin secretion by glucagon like peptide 1 1.94E−03 6.08E−03 1.47E−05 9.99E−05 2.67E−03 1.96E−05
Regulation of ornithine decarboxylase 7.81E−04 1.38E−01 7.89E−05 1.51E−01 1.50E−02 2.74E−03
Serotonin neurotransmitter release cycle 7.12E−03 3.91E−06 1.47E−05 8.76E−05 4.97E−06 1.96E−05
Signaling by WNT 8.24E−04 1.00E−02 1.47E−05 4.25E−02 4.45E−03 1.03E−04
Signaling by NGF 2.25E−03 9.51E−04 1.47E−05 6.17E−03 1.41E−03 1.96E−05
Trafficking of AMPA receptors 3.27E−02 1.82E−04 1.47E−05 4.20E−02 2.30E−03 1.96E−05
Trafficking of GLUR2 containing AMPA receptors 1.07E−01 2.70E−04 2.74E−05 1.31E−01 4.56E−03 4.62E−04
Transmission across chemical synapses 5.94E−06 2.29E−11 1.47E−05 1.66E−08 1.53E−08 1.96E−05
Q values are shown for each region, and for the weighted average (AVG) of the two regions in the meta-analysis.
BA, Brodmann area.
Table 3 |Top pathways identified by genes showing negative correlations with VSNL1 expression.
Pathway Age under 50 Age over 50
BA 47 BA 11 AVG BA 47 BA 11 AVG
KEGG
Allograft rejection 1.00E+00 1.00E+00 1.00E+00 1.38E−01 5.40E−01 3.37E−02
Autoimmune thyroid disease 1.00E+00 1.00E+00 1.00E+00 1.38E−01 5.40E−01 3.37E−02
Cell adhesion molecules CAMS 2.23E−01 8.54E−01 6.73E−02 4.19E−02 4.75E−01 2.78E−03
Cytokine–cytokine receptor interaction 2.23E−01 5.94E−01 4.17E−02 4.19E−02 1.68E−01 1.20E−03
Focal adhesion 6.69E−02 1.00E+00 3.85E−02 2.50E−01 1.00E+00 1.88E−01
Graft versus host disease 1.00E+00 1.00E+00 1.00E+00 1.38E−01 5.40E−01 3.37E−02
NOTCH signaling pathway 2.98E−01 1.00E+00 3.27E−01 1.38E−01 7.50E−01 4.69E−02
Pathways in cancer 8.23E−01 1.00E+00 4.25E−01 9.59E−02 6.10E−01 1.92E−02
Propanoate metabolism 3.54E−01 1.00E+00 4.30E−01 1.49E−01 4.75E−01 3.37E−02
Proximal tubule bicarbonate reclamation 1.83E−01 6.41E−01 3.85E−02 1.49E−01 2.43E−01 9.36E−03
Regulation of actin cytoskeleton 6.05E−02 8.29E−01 1.57E−02 3.32E−01 1.00E+00 2.25E−01
BIOCARTA
MCALPAIN pathway 9.06E−02 1.00E+00 4.83E−02 1.91E−01 1.00E+00 1.61E−01
REACTOME
Ethanol oxidation 1.00E+00 1.00E+00 1.00E+00 2.79E−01 4.19E−01 4.69E−02
GAP junction trafficking 1.59E−01 5.29E−01 1.57E−02 8.51E−01 5.35E−01 2.85E−01
Immunoregulatory interactions between a lymphoid and a
non-lymphoid cell
3.51E−01 1.00E+00 2.02E−01 7.45E−02 4.67E−01 5.83E−03
Integrin cell surface interactions 9.06E−02 5.29E−01 1.00E−02 1.73E−01 9.45E−01 8.26E−02
NOTCH HLH transcription pathway 9.06E−02 1.00E+00 6.51E−02 2.78E−01 4.11E−01 4.48E−02
Q values are shown for each region, and for the weighted average (AVG) of the two regions in the meta-analysis.
BA, Brodmann area.
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may interact to underlie the association of VSNL1 genetic variation
with psychosis in AD, is not known.
VSNL1 was co-expressed with genes in several distinct path-
ways. This included co-expression with genes identified with AD
pathways and genes involved in mediating synaptic plasticity
mechanisms such as long-term potentiation, long-term depres-
sion, and trafficking of AMPA receptors. These findings support
a role for Vilip1 in these processes, as co-expressed genes tend to
be related functionally (43). However, the specific nature of any
functional relationship cannot be readily inferred,as co-expression
can arise from many sources (44). For example, gray matter
homogenates are a mixture of many cell types. Multiple genes that
are specifically enriched in a single cell type, e.g. microglia, may be
identified as co-expressed (43, 45). Alternatively, genes may share
a mechanism regulating their transcription such as a transcription
factor in common (46), proximity within the linear sequence of
DNA leading to synchronous transcription (47), or colocalization
within the spatial configuration of chromosomes (48). Similarly,
epigenetic control of transcription via histone acetylation and
methylation can lead to co-expression of neighboring genes (49).
Finally, mRNA degradation via microRNA binding may also lead
multiple targets of a given microRNA to demonstrate correlated
expression (50).
In summary, VSNL1 is co-expressed with functional groups
and gene transcripts in AD pathways, including APP itself and
pathways implicated in synaptic pathology in AD. These findings
provide an unbiased link between VSNL1 and molecular mech-
anisms of AD. However, whether increased expression of APP
may drive increased VSNL1 expression, increased VSNL1 expres-
sion drives increased APP expression, or both are concurrently
altered downstream of another factor will need to be evaluated
in model systems. For example, evaluation of VSNL1 expression
in transgenic mouse models of AD, or evaluation of APP expres-
sion after knockdown of VSNL1 would be indicated. Similarly,
whether altering VSNL1 expression modifies synaptic pathology
in AD would benefit from testing within in vitro and/or genetic
mouse models.
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